Skip to
  1. Homepage
  2. Rare diseases
  3. Search
Simple search

Simple search

*
(*) mandatory field





 

Other search option(s)

Fragile X syndrome

Orpha number ORPHA908
Synonym(s) FRAXA syndrome
FXS
FraX syndrome
Martin-Bell syndrome
Prevalence 1-5 / 10 000
Inheritance X-linked dominant
Age of onset Childhood
ICD-10
  • Q99.2
ICD-O -
OMIM
UMLS
  • C0016667
  • C0751156
MeSH
  • D005600
MedDRA
  • 10017324
SNOMED CT
  • 254287005
  • 613003

Summary

Fragile X syndrome (FXS) is a rare genetic disease associated with mild to severe intellectual deficit that may be associated with behavioral disorders and characteristic physical features.

Prevalence is estimated at approximately 1/2,500 (prevalence of the full mutation allele) to 1/4,000 (prevalence of symptomatic cases) for both genders.

FXS presents with a variable clinical phenotype. In males, the disease presents during childhood with delayed developmental milestones (motor and/or language delay). In males and in 50% of females, intellectual disorders associated with behavioral problems and/or dysmorphic features appear. Recurrent otitis and sinusitis, and seizures can also be observed. Intellectual deficit vary from mild learning problems with a normal IQ to severe intellectual deficit and may include problems with working and short-term memory, executive function, and mathematic and visuospatial abilities. Behavioral anomalies can be mild, like mood instability, to severe, like autism. Autistic-like behavior can include hand flapping, poor eye contact, hand biting, gaze avoidance, tactile defensiveness and behavioral dysinhibition. Mood disorders, anxiety and aggressive behavior can be present. In females, intellectual and behavioral disorders are mild and usually consist of emotional and learning problems. In both sexes, physical features are subtle and may include a narrow and elongated face, prominent ears and forehead, hyperextensible finger joints, pes planus, and macroorchidism in postpubertal males.

FXS is caused by the transcriptional silencing of the FMR1 gene (Xq27.3) due to the progressive expansion and subsequent methylation of (CGG)n trinuleotide repeats in the 5'-untranslated region of the gene. These full mutations originate from unstable alleles called premutations (55-200 CGG repeats). Premutations are associated with phenotypes distinct from FXS including a risk of premature ovarian insufficiency in women, and the fragile X-associated tremor/ataxia syndrome (see this term). In some rare cases, FXS was shown to result from intragenic FMR1 point mutations rather than expansion of a CGG repeat. FMR1 codes for the FMRP protein, an RNA-binding protein that regulates protein synthesis and other signaling pathways in neuronal dendrites. FMR1 silencing is thought to reduce synaptic plasticity and modulation throughout the brain including the hippocampus.

Diagnosis cannot be based on the clinical picture as physical features may be mild or absent and is therefore based on genetic testing performed for all patients with an intellectual deficit or autism.

The differential diagnosis includes other X-linked intellectual deficits, Sotos syndrome, microdeletion syndromes (e.g. velocardiofacial syndrome), fetal alcohol syndrome (see these terms) or idiopathic autism.

Prenatal diagnosis is based on Southern blot hybridization on samples of chorionic villi or amniotic fluid.

FXS is an X-linked dominant disorder with reduced penetrance in females. Genetic counseling should be offered to families of an affected individual in order to explain the mode of inheritance of the mutations.

Management is symptom-based and requires a multidisciplinary approach. Treatment with drugs, like stimulants and selective serotonin reuptake inhibitors (SSRIs) (anxiety, obsessive-compulsive behaviors), and atypical antipsychotic agents (self-injury, aggressive behaviors, and autism), should be combined with speech therapy, sensory integration occupational therapy, individualized educational plans, and behavioral interventions. New targeted treatments for FXS (mGluR5 antagonists, GABA A and B agonists, minocycline) are now being studied and early reports are promising. These new treatments are likely to modify the lifetime course of FXS and to improve the prognosis.

Currently most boys and approximately 30% of girls with FXS will have significant intellectual deficit in adulthood.

Expert reviewer(s)

  • Pr Randi HAGERMAN

(*) Required fields.

Attention: Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.


Captcha image

Detailed information

Summary information
Practical genetics
  • EN (2008,pdf)
Guidance for genetic testing
  • EN (2011,pdf)
Article for general public
  • FR (2012,pdf)
Clinical genetics review
  • EN (2012)
Disability factsheet
  • FR (2013,pdf)
Get Acrobat Reader
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.